Stay updated on CM-24 Combo Study With Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the CM-24 Combo Study With Pembrolizumab Clinical Trial page.

Latest updates to the CM-24 Combo Study With Pembrolizumab Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page’s interface/version indicator was incremented from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a minor site update rather than a change to the study record.SummaryDifference0.0%

- Check26 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision: v3.5.0 is now displayed, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This update does not change the study details or site content.SummaryDifference0.0%

- Check90 days agoChange DetectedGastric cancer was added to the list of studied conditions and a Genetics/Rare Diseases Information Center resource was included. The page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.2%

- Check97 days agoChange DetectedRevision: v3.4.1 was added and v3.4.0 was removed. This change does not affect study data, eligibility, or functionality; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to CM-24 Combo Study With Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CM-24 Combo Study With Pembrolizumab Clinical Trial page.